South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...
Mar 18, 2025 (Gmt+09:00)
Cookies on KED Global
We use cookies to provide the best user experience. By continuing to browse this website, you will be considered to accept cookies. Please review our Privacy Policy to learn our cookie policy.